VXM01 is an orally-administered vaccine that elicits a systemic T-cell response targeting VEGFR-2. Here, Wolfgang Wick, MD, from the German Cancer Research Center, Heidelberg, Germany, discusses the results of the latest clinical trial investigating the use of this vaccine in patients with progressive glioblastoma who have failed radiochemotherapy with temozolomide. Treated patients demonstrated a direct response to the vaccine, and adverse events were minimal. The next step in this trial involves the use of a checkpoint inhibitor to further increase the efficacy of the vaccine. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.